WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013053767) TREATMENT FOR RHEUMATOID ARTHRITIS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/053767    International Application No.:    PCT/EP2012/070074
Publication Date: 18.04.2013 International Filing Date: 10.10.2012
IPC:
C07K 16/28 (2006.01), A61P 19/02 (2006.01)
Applicants: MEDIMMUNE LIMITED [GB/GB]; Milstein Building Granta Park Cambridge Cambridgeshire CB21 6GH (GB)
Inventors: GODWOOD, Alex; (GB).
MAGRINI, Fabio; (US)
Agent: WINTER, Christopher Spencer; Medimmune Limited Milstein Building Granta Park Cambridge Cambridgeshire CB21 6GH (GB)
Priority Data:
61/545,359 10.10.2011 US
61/556,974 08.11.2011 US
Title (EN) TREATMENT FOR RHEUMATOID ARTHRITIS
(FR) TRAITEMENT DE LA POLYARTHRITE RHUMATOÏDE
Abstract: front page image
(EN)Treatment of rheumatoid arthritis (RA) to provide clinical benefit in patients, including decrease in DAS28-CRP by more than 1.2 and/or improvement determined by ACR20, ACR50 or ACR70, comprising administering therapeutic antibody mavrilimumab or other inhibitor targeted to Tyr-Leu-Asp-Phe-Gln motif of granulocyte/macrophage colony stimulating factor receptor alpha (GM-CSFRα). Use of GM-CSFRα inhibitors such as mavrilimumab to enhance clinical benefit in RA patients receiving stable dose of DMARDs, particularly methotrexate.
(FR)L'invention concerne des traitements de la polyarthrite rhumatoïde (RA) pour fournir un bénéfice clinique chez des patients, comprenant la diminution de DAS28-CRP de plus de 1,2 et/ou l'amélioration déterminée par ACR20, ACR50 ou ACR70, comprenant l'administration d'un anticorps thérapeutique, mavrilimumab, ou un autre inhibiteur ciblé vers le motif Tyr-Leu-Asp-Phe-Gln du récepteur alpha du facteur de stimulation des colonies de granulocytes/macrophages (GM-CSFRα). L'invention concerne l'utilisation d'inhibiteurs de GM-CSFRα, tels que mavrilimumab, pour améliorer le bénéfice clinique chez des patients RA recevant une dose stable de DMARD, en particulier de méthotrexate.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)